1063733-77-6

Basic information

• Product Name: 2-(3,5-difluorophenoxy)propan-2-ol
• Synonyms: 2-(3,5-difluorophenoxy)propan-2-ol
• CAS NO: 1063733-77-6
• Molecular Weight: 172.175
• Mol File: 1063733-77-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-(3,5-difluorophenoxy)propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,5-difluorophenoxy)propan-2-ol(1063733-77-6)
• EPA Substance Registry System: 2-(3,5-difluorophenoxy)propan-2-ol(1063733-77-6)

Safety Data

• Hazardous Substances Data: 1063733-77-6(Hazardous Substances Data)

Upstream product

• 62351-47-7 3,5-difluorophenylmagnesium bromide 
• 67-64-1 acetone 
• 872181-59-4 rac-1-(3,5-difluorophenyl)ethan-1-ol 
• 32085-88-4 3,5-difluorobenzaldehyde 
• 75-16-1 methylmagnesium bromide 
• 123577-99-1 3′,5′-difluoroacetophenone 

Downstream Products

• 1355011-37-8 (2-(3,5-difluorophenyl)propan-2-yloxy)triisopropylsilane 
• 1620013-88-8 4-{(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-methylpiperidin-1-yl}-3-[({6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridin-2-yl}carbonyl)amino]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate 
• 1620013-89-9 tert-butyl ((3S,5R)-1-{3-[({6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridin-2-yl}carbonyl)amino]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl}-5-methylpiperidin-3-yl)carbamate 
• 1620013-87-7 N-{4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridine-2-carboxamide 
• 1355011-40-3 6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridine-2-carboxylic acid 
• 1620013-80-0 tert-butyl ((3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-{5-[({6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridin-2-yl}carbonyl)amino]-2,3-dihydrofuro[2,3-b]pyridin-4-yl}-5-methylpiperidin-3-yl)carbamate 
• 1620013-79-7 N-{4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-2,3-dihydrofuro[2,3-b]pyridin-5-yl}-6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridine-2-carboxamide 
• 1620014-27-8 4-[(3S,5R)-3-[(tert-butoxycarbonyl)amino]-5-(trifluoromethyl)piperidin-1-yl]-3-[({6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridin-2-yl}carbonyl)amino]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate 
• 1620014-24-5 N-{4-[(3S,5R)-3-amino-5-(trifluoromethyl)piperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridine-2-carboxamide 
• 1355011-39-0 methyl 6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridine-2-carboxylate 
• 1586045-27-3 2-(2,6-difluoro-4-(2-hydroxypropan-2-yl)phenyl)thiazole-4-carboxylic acid 
• 1586041-35-1 N-(5-((2S,5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluoro-4-(2-hydroxypropan-2-yl)phenyl)thiazole-4-carboxamide 
• 1395993-56-2 1,3-difluoro-5-(2-methoxypropan-2-yl)benzene 
• 1355011-38-9 (2-(3,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yloxy)triisopropylsilane 

Relevant articles and documents

PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS

The present disclosure describes pyridineamine compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer, immune disorders and other diseases. Formula (I).

N-(3-PYRIDYL) BIARYLAMIDES AS KINASE INHIBITORS

The present invention provides a compound of formula (I): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.

NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS

The present invention provides a compound of formula (A): I as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.